Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What should the SP be?

<< Previous

Bullboard Posts

Next >>

Comment by CoffeeBeanson Aug 21, 2021 7:37am

267 Views

Post# 33744595

RE:What should the SP be?

Today $1.15... it might drop to a dollar or below in the short term... but this will jump once they figure this out and jump again on the next catalyst so by this time next year will be back in the $3 range.....If they don't figure this out then it will be $.50 with no volume for a long t. If they don't figure this out then it will be $.50 with no volume.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks